Lipella jumps after inflammatory disease drug found safe in study

Lipella Pharmaceuticals

11/02/2025 11:50

** Shares of Pittsburgh-based drug developer Lipella
Pharmaceuticals  LIPO.O  rise 68.20% to $5.14 premarket 
    ** LIPO says its experimental drug, LP-310, showed a strong
safety profile in a small study of 24 patients with oral lichen
planus (OLP), a chronic inflammatory disease that affects mucous
membranes inside the mouth 
    ** Co says no drug-related serious adverse events were found
in study, and no patients dropped out 
    ** LIPO says LP-310, an oral rinse topical treatment, helped
meaningfully reduce pain, ulceration, and inflammation for
patients in the study
    ** Co plans to submit marketing application for LP-310 to
the FDA in H2 2025
    ** In the last 12 months, the stock has fallen 63.34% 

 (Reporting by Siddhi Mahatole)
 ((siddhiprabhanjan.mahatole@thomsonreuters.com))